Danish Drama: Genmab Drops $8B on Cancer Cure Hope Seller
In a move that screams 'we have billionaire money to burn,' Danish biotech bigwig Genmab announced it plans to acquire Merus, the brainiac behind a shiny new head and neck cancer drug, for around $8 billion. That's $8 billion, or roughly the cost of buying every Danish pastry in Copenhagen twice over. This deal lands Genmab firmly in Life Sciences prime, scheming to turn biology into cold, hard kroner. With cancer therapy innovation like this on the line, letâs hope Merus's drug fights neck and head tumors better than Genmab fought that price tag.
Share the Story
Genmab just dropped $8 billion on Merus like itâs Black Friday for biotech, apparently 'saving cancer patients' is easier when you have a billionaire bankroll appearing out of nowhere.
Buying a head and neck cancer drug developer for $8 billion is peak pharmaceutical flexâGenmabâs basically saying, 'Weâll fix your cells, but first, show us the money.'
Genmab buying Merus is like paying $8 billion for a Tesla upgradeâyouâre still hoping it doesnât break down, but hey, it looks promising!
Source: Statnews | Published: 9/29/2025 | Author: Andrew Joseph
More Articles in Business
Budget Airline Drops Deportation Flights After Discovering Politics Isnât Free
ICE Agent Did Exactly What He Was Taught, But No One Knows What That Means
Ed Sheeran Launches 2026 LOOP Tour, Tickets Not Looping Into Your Wallet
Billionaire Bros Move T-Rex LLC Out of California to Avoid Paying Taxes; Dinosaur Surprised
Grandfather Gifts $1,500 with Guest Star Role for Financial Advisor
Facebook Exec Jumps Off Career Cliff to Build Giant iPhone Flop
Man Moves to Spain for Sun, Pays in Airport Commute Hours Instead of Pounds
New Berkshire CEO Gets $25M While Buffett Lived on $100K and Sandwiches
